心脏神经移除作为功能性AV阻塞的治疗方法,在AVNRT移除后出现晚期的AVNRT移除
Rodolfo San Antonio1,2, Andrea Di Marco1,2, Jordi Mercé1,2
1Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Spain.
Journal of cardiovascular electrophysiology
|May 4, 2025
概括
心脏神经移除 (CNA) 提供了一个有前途的替代方案,以节律起器的晚发性心房阻塞 (AVB) 后心动减退. 这项研究表明,CNA有效地控制了三名患者的AVB症状,防止了昏迷的复发.
科学领域:
- 电力生理学 电力生理学
- 心律不整的管理心律不整管理
- 干预心脏病学 干预心脏病学
背景情况:
- 心房静脉阻塞 (AVB) 是心房静脉节点回入性心力衰竭 (AVNRT) 切除后的一种罕见但严重的并发症.
- 接受AVNRT切除的患者面临晚期AVB和心脏起器植入的风险增加.
- 心脏神经移除 (CNA) 是昏迷和导电障碍的潜在替代方案,但其在AVNRT后AVB中的作用尚未确定.
研究的目的:
- 为了评估心脏神经移除 (CNA) 在成功进行AVNRT移除后管理晚发性阳性心房阻塞 (AVB) 的疗效.
- 在这个特定的患者群体中,评估CNA作为心脏起器植入的替代方案.
- 调查针对特定状的CNA的程序和临床结果.
主要方法:
- 对三名因晚发性AVB后AVNRT切除而出现昏睡的患者进行前性研究.
- 通过使用热素测试来评估下和上导电.
- 使用Ensite X EP系统进行双心CNA,使用射频能量准下和左上腺.
- 成功的定义是废除了热素反应,没有昏迷复发,在霍尔特监测上传导正常.
主要成果:
- 在所有三名患者中都取得了急性手术成功,在射频切除后,温克巴赫点的降低.
- 在CNA后的氨酸和倾斜测试中,分别显示了保存的导电和血管抑制反应.
- 在6至13个月的随访期间没有观察到昏迷复发,霍尔特监测结果正常.
结论:
- 心脏神经移除 (CNA) 显示出承诺,作为AVNRT移除后晚发动AVB的节律起器的替代方案.
- 准下神经结交 (IPSGP) 可能对成功的结果至关重要.
- 需要进行更大规模的研究来证实这种人群中CNA的长期疗效和最佳技术.
相关概念视频
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
674
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
674
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
302
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
302
Disturbances in Heart Rhythm
705
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
705
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
640
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
640
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.0K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
807
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
807


